Unveiling the Potential of JAK Inhibitors in Inflammatory Bowel Disease

Background: Janus kinase (JAK) inhibitors represent a novel class of oral therapies showing efficacy in treating ulcerative colitis (UC) and Crohn’s disease (CD), challenging conventional treatment paradigms. Summary: This review provides an overview of the potential novel uses of JAK inhibitors, fo...

Full description

Bibliographic Details

Main Authors:	Shahed Kamal, Sheng Wei Lo, Samantha McCall, Beverly Rodrigues, Andrew H. Tsoi, Jonathan P. Segal
Format:	Artigo
Language:	Inglês
Published:	MDPI AG 2024-05-01
Series:	Biologics
Subjects:	ulcerative colitis Janus kinase inhibitors tofacitinib filgotinib upadacitinib
Online Access:	https://www.mdpi.com/2673-8449/4/2/12
Tags:	Add Tag No Tags, Be the first to tag this record!